The pre-clinical studies by actively immunizing tumor endothelial expressing antigens via DNA vaccines and protein pulsed DCs successfully inhibited tumor growth and increased the infiltration of CD8+ T cells in the TME. This evidence concerns the gene CD8A and neoplasm.